Rare disease focus Target neuromuscular disease programs with potential for strategic partnerships or grant-funded collaborations, emphasizing the platform’s ability to model disease states and screen repurposed compounds for FSHD, SMA, and related conditions.

Clinical acceleration Leverage the proprietary skeletal muscle differentiation method to offer earlier preclinical readouts and disease relevance, positioning as a value-add for pharma companies seeking faster lead prioritization and regulatory-ready candidates.

Specialized library Promote access to a curated, low-toxicity repurposed compound library as a differentiator for de-risked screening campaigns, appealing to partners aiming to shorten timelines and reduce development risk.

Early-stage collaboration Pursue sponsored research and milestone-based partnerships with small and mid-size biotech firms that lack in-house neuromuscular screens, offering a scalable path from discovery to lead optimization.

Strategic positioning Highlight San Diego base and roots from a multiregional group to build credibility, while aligning with larger CROs or contract manufacturers for scale-up, formulation, and translational studies as potential growth avenues.